Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neotherapuetics possibly has a breakthrough drug - NEOT -- Ignore unavailable to you. Want to Upgrade?

To: Marty who wrote (20)	8/15/1999 8:10:00 PM
From: Marty	Read Replies (1) \| Respond to of 204

Here is an article with some interesting details from the Ph2a tests published in June that most people missed: ------------------------ Neotrofin Effective In Alzheimer's Disease Treatment IRVINE, CA -- June 2, 1999 -- Recently completed phase IIa clinical trial of NeoTherapeutics, Inc.'s Neotrofin(TM) in patients with Alzheimer's disease show that the drug produces significant clinical improvements in cognitive function, behavioural symptoms and disease severity. The data from this study was presented today at the 39th annual meeting of the New Clinical Drug Evaluation Unit (NCDEU), in Boca Raton, FL. Steven Targum, M.D., of Clinical Studies Ltd., the principle investigator of this clinical trial, presented data describing the use of NeoTherapeutics' novel drug as a potential treatment for patients with mild to moderate Alzheimer's disease. Seventy-five subjects were enrolled in the double-blind study which tested Neotrofin at three dose levels or placebo for 28 days of treatment. These subjects were evaluated again after a 28 day period in which no drug was given, to determine potential longer term effects of the drug. In patients with Alzheimer's disease, the Neotrofin treated group showed an improvement from baseline testing in the ADAS-cog, a measure of cognitive functioning, after 28 days of administration. Total ADAS-cog scores improved in 72 percent of patients receiving the 150mg dose. The Global Behave-AD test, a measure of behavioural symptoms such as aggressiveness and anxiety, revealed statistically significant positive differences between drug groups and the placebo group. Additionally, the CIBIC-plus, a measure of overall disease severity, demonstrated a marked improvement in the drug treated groups and the positive effects of the drug were observed for an additional 28 days after the drug was stopped. "Improvements in memory function and behaviour suggest that Neotrofin may have therapeutic benefit in patients with Alzheimer's disease," Dr. Targum said. "Larger studies of longer duration with Neotrofin are needed to ascertain the sustained cognitive benefit of this drug and evaluate the potential to modify the progression of Alzheimer's disease." Neotrofin is being developed for nerve repair and regeneration, with Alzheimer's disease as its first clinical indication. Pre-clinical studies have demonstrated that Neotrofin can control the production of multiple natural neurotrophic factors and restore function in animal models of aging, brain injury and spinal cord injury. ------------------------------- You would think the stock would be higher now.

To: Marty who wrote (20)	9/28/1999 9:06:00 PM
From: Marty	Read Replies (2) \| Respond to of 204

It's hard to believe that NEOTW went down today a full half point, almost 11%, on 400 warrants volume. That is $1,600 total value for all the volume for the warrants today and they took it down a full half point! Does anyone else consider this an outrage? Does it mean that there is so little interest in the warrants ( and it's the same situation with the stock) that they can't get enough market makers to get a fair market? Does it mean that they do have enough market makers in the stock but that the market makers take advantage of their position and don't care who sees it? Or is it the market makers have so many warrants on hand already that they are unwilling to buy even 400 more unless they can get them for 11% less than the last trade? Was there such a deluge of sell orders on the warrants that they couldn't afford to take a chance unless they got a big, big, discount on these trades? The way I figure it, the warrants are a better bet than the stock if the drug ever gets to market. BUT if it is going to be such a capricious market or you get raped if you want to sell even 400 hundred warrants ... what's the sense of it? One of the last assurances you have with this stock is that if you buy it you think you can sell it some day close to the market price. If that isn't true, what's left?